STAT3 and pancreatic neoplasm: In agreement with these observations, monoclonal antibodies targeting the CD44s isoform reduce CSC percentage in cultured pancreatic cancer cells and in xenograft mouse models, along with downregulating STAT3 levels and STAT3-mediated target gene expression (79).